Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

被引：0
|
作者：
Taiki Hakozaki
Yukio Hosomi
Akihiro Shimizu
Rui Kitadai
Kie Mirokuji
Yusuke Okuma
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Thoracic Oncology and Respiratory Medicine
[2] National Cancer Center Hospital,Department of Thoracic Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Polypharmacy; Non-small cell lung cancer; Overall survival; Geriatric oncology; Comorbidity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2659 / 2668
页数：9
相关论文
共 50 条
  • [21] Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
    Kim, Kyung Hwan
    Hur, Joon Young
    Koh, Jiae
    Cho, Jinhyun
    Ku, Bo Mi
    Koh, June Young
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    Shin, Eui-Cheol
    IMMUNE NETWORK, 2020, 20 (06) : 1 - 11
  • [22] Immune Cell Profiling of Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Antibodies
    Kim, K. H.
    Hur, J. Y.
    Ku, B. M.
    Koh, J.
    Ahn, M.
    Shin, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S340 - S340
  • [23] Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Su, Chaoyue
    Wang, Hui
    Liu, Yunru
    Guo, Qiaoru
    Zhang, Lingling
    Li, Jiajun
    Zhou, Wenmin
    Yan, Yanyan
    Zhou, Xinke
    Zhang, Jianye
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer
    Woodford, Rachel
    Zhou, Deborah
    Lord, Sarah J.
    Marschner, Ian
    Cooper, Wendy A.
    Lewis, Craig R.
    John, Thomas
    Yang, James Chih-Hsin
    Lee, Chee Khoon
    FUTURE ONCOLOGY, 2022, 18 (14) : 1793 - 1799
  • [25] Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
    Wang, Luyao
    Ma, Qingxia
    Yao, Ruixue
    Liu, Jia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 79
  • [26] Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
    Chung, Jae Heun
    Ha, Jong Seong
    Choi, Jaewoo
    Kwon, Sang Mo
    Yun, Mi Sook
    Kim, Taehwa
    Jeon, Doosoo
    Yoon, Seong Hoon
    Kim, Yun Seong
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (02) : 316 - +
  • [27] Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
    Yin, Jianqiong
    Wu, Yuanjun
    Yang, Xue
    Gan, Lu
    Xue, Jianxin
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade
    Yoshida, Hironori
    Nomizo, Takashi
    Ozasa, Hiroaki
    Tsuji, Takahiro
    Funazo, Tomoko
    Yasuda, Yuto
    Ajimizu, Hitomi
    Yamazoe, Masatoshi
    Kuninaga, Kiyomitsu
    Ogimoto, Tatsuya
    Hosoya, Kazutaka
    Itotani, Ryo
    Sakamori, Yuichi
    Kim, Young Hak
    Hirai, Toyohiro
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 317 - 325
  • [29] Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review
    Takamori, Shinkichi
    Toyokawa, Gouji
    Takada, Kazuki
    Shoji, Fumihiro
    Okamoto, Tatsuro
    Maehara, Yoshihiko
    CLINICAL LUNG CANCER, 2018, 19 (01) : 12 - 16
  • [30] PD-L1 as a predictive factor for non-small-cell lung cancer prognosis
    Chen, Long
    Zhu, Xian-Ze
    Zhao, Shi-Jie
    Yang, Qiang-Wei
    LANCET ONCOLOGY, 2024, 25 (06): : e233 - e233
12345